Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors.
Polypeptide growth factors (PGFs), mainly those of the fibroblast growth factor (FGF) family, have been shown to be capable of regulating angiogenesis. Although many data have been accumulated during this last year on the mechanism of action of PGF, little is known about a possible identification of second messengers signalling to the cell the occupancy of the receptor by its ligand. We have previously proposed that arachidonic acid or its derivatives may play a role as PGF second messengers. In the present paper we described a modification of the chorioallanthoic membrane (CAM) technique, involving the use of labelled sulphate to follow the angiogenic process. Thus we have been able to correlate morphological observation of CAMs development with incorporation of labelled sulphate in a stable form. Here we show that, as expected, PGF as endothelial cell growth factor (ECGS) or basic fibroblast growth factor (bFGF) potentiate the incorporation of radioactivity into CAMs at concentrations which for bFGF are of the order of 1.5 micrograms/egg. This effect can be correlated to the generation of prostanoids by two kinds of approach: A) PGE1 injected into eggs was capable of strongly increasing labelling of CAMs; B) Indomethacin had a dramatic effect on embryo survival as well as on CAM development, decreasing both at very low concentration (50 survival rate observable at 2 micrograms/egg). Finally vanadate, which is known to inhibit tyrosine phosphatase, was capable of potentiating the effect of PGF on angiogenesis. Thus it appears that products of the prostaglandin H synthase pathway behave as mediators of PGF control of angiogenesis.
D000482:Allantois / Q000098:blood supply; D000527:Alprostadil / Q000494:pharmacology*; D000818:Animals; D002642:Chick Embryo; D002823:Chorion / Q000098:blood supply; D004790:Enzyme Induction; D005346:Fibroblast Growth Factors / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis* / Q000235:genetics; D015290:Second Messenger Systems
D006133:Growth Substances; D005346:Fibroblast Growth Factors; D011451:Prostaglandin-Endoperoxide Synthases; D000527:Alprostadil; D007213:Indomethacin